Regulatory Developments in the Chinese Healthcare Industry in 2023

February 02, 2024 | BY

Susan Mok

In 2023, the healthcare industry in China was subject to significant legislative advancements and reforms aimed at addressing industry concerns and promoting innovation. Hanshuo Zhou and Xiaoyun Wang of Jingtian & Gongcheng summarize the key events, and provide a reflective review based on their' practical experience

Summary

  • In 2023, there were a number of important legislative and regulatory developments across China's healthcare sector
  • This included a number of measures targeting the cell and gene therapy (CGT) industry, particularly in relation to foreign investment
  • Ethical reviews and robust anti-corruption programs were also a key feature of the past year

 

 

This premium content is reserved for
China Law & Practice Subscribers.

  • A database of over 3,000 essential documents including key PRC legislation translated into English
  • A choice of newsletters to alert you to changes affecting your business including sector specific updates
  • Premium access to the mobile optimized site for timely analysis that guides you through China's ever-changing business environment
For enterprise-wide or corporate enquiries, please contact our experienced Sales Professionals at +44 (0)203 868 7546 or [email protected]